Rebalix
iShares · sheet of 10 September 2026
iShares · sheet of 10 September 2026ETF sheet · official issuer and register data
iShares Nasdaq US Biotechnology UCITS ETF
BTEC · IE00BYXG2H39 · USD · domicile Ireland
Equity · United States · Health care · Small capSFDR art. 6
Index tracked: NASDAQ Biotechnology NET Index
- TER
- 0.35%+ trans. 0.02%
- Fund size
- 1 bn EUR
- Tracking difference
- −0.17%3-year avg
- 🇮🇹 tax rate
- 26.00%white list 0.00%
- Replication
- Physical
- Income
- Accumulating
Launch 19 Oct 2017 · costs from the KID as of 2 Sept 2026 · 255 securities held · 8 venues (ESMA register)
The fund’s objective — in the issuer’s words
From the Key Information Document (KID) · 4 Aug 2026
The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund’s assets, which reflects the return of the NASDAQ Biotechnology Index, the Fund’s benchmark index (Index). The Share Class, via the Fund is passively managed, and aims to invest so far as possible and practicable in the equity securities (e.g. shares) that make up the Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology…
Performance since series start (in euro) — base 100
19 Oct 2017 → 31 Aug 2026 · dividends reinvested where declared by the issuer · converted at ECB rates
Returns in euro
| 1 year | +53.3% |
| 3 years | +63.9% |
| 5 years | +38.2% |
| 10 years | series too young |
| Since series start | +112.4% |
Risk · 1 / 3 / 5 years
| Volatility (ann.) | 21.59% | 20.94% | 22.18% |
| Max drawdown | −8.49% | −23.98% | −37.31% |
| Sharpe | 1.80 | 0.83 | 0.26 |
| Sortino | 2.89 | 1.22 | 0.37 |
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · BTEC · IE00BYXG2H391
RebalixBTEC · IE00BYXG2H39 · sheet of 10 September 2026
Tracking difference — year by year
Fund minus index, complete calendar years · from issuer-declared series
| Year | Fund | Index | TD |
|---|---|---|---|
| 2025 | +32.88% | +33.12% | −0.25% |
| 2024 | −0.96% | −0.81% | −0.14% |
| 2023 | +4.22% | +4.33% | −0.11% |
| 2022 | −10.53% | −10.36% | −0.17% |
| 2021 | −0.40% | −0.17% | −0.23% |
Holdings
Portfolio as declared by the issuer · 31 Aug 2026 · 255 securities · top-10 weight = 44.2%
| Top holdings | Weight |
|---|---|
| 8.7% | |
| 8.3% | |
| 7.4% | |
| 5.3% | |
| 3.6% | |
| 2.8% | |
| 2.1% | |
| 2.1% | |
| 2.1% | |
| 1.8% |
Countries (% of fund)
Sectors (% of fund)
Listing venues
ESMA register (FIRDS) and official exchange lists
2B70 · Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 16 unmapped venues (MTF, RFQ, professional)
Official documents
Clickable links in the PDF
The live sheet, always up to date
rebalix.com/en/etf/IE00BYXG2H39
Series, distributions, holdings and documents refresh daily.
rebalix.com/en/etf/IE00BYXG2H39
Series, distributions, holdings and documents refresh daily.
Sheet produced on 10 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.
Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.
Rebalix · BTEC · IE00BYXG2H392